Erasca posts Q1 net loss of $183.4M; cash $408.5M; advances ERAS-0015 with robust early data

Erasca, Inc.

2026-Q1 EPS reported -$0.60 vs consensus -$0.21 ▼ miss (-181.6%)

Net loss of $183.4M ($0.60 per share) vs $31.0M loss a year ago; includes $150M in-process R&D charge for license expansion.
Cash and securities of $408.5M as of Mar 31, 2026, expected to fund ops into H2 2028; completed $258.8M public offering in Jan.
ERAS-0015 dose escalation showed robust responses in KRAS G12X NSCLC and PDAC with favorable safety; no TRAE discontinuations.
Monotherapy expansion and combo with panitumumab initiated ahead of schedule; data expected H1 2027.
Entered CTCSA with Merck for ERAS-0015 + KEYTRUDA combo; also with Tango for PRMT5 inhibitor combo.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Erasca, Inc. reported financial results for the fiscal quarter ended March 31, 2026.

Period: the fiscal quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 11, 2026, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Erasca, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-216739

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.